

---

# Toleranzia brings forward publication of annual report

**Toleranzia AB (publ) has decided to bring forward the publication of the annual report for the financial year 2024 to April 23, 2025.**

The previous date for publication of the annual report for the financial year 2024 was April 30, 2025, but is now brought forward to April 23, 2025.

**For further information, please contact**

Charlotte Fribert - CEO, Toleranzia AB

Tel: +46 763 19 98 98

E-post: [charlotte.fribert@toleranzia.com](mailto:charlotte.fribert@toleranzia.com)

**About Toleranzia AB (publ)**

Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed.

Toleranzia's shares are listed on Nasdaq First North Growth Market and Svensk

Kapitalmarknadsgranskning AB, +46 (0)8 913 008, [ca@skmg.se](mailto:ca@skmg.se), is the company's Certified Adviser.

**Attachments**

---

[Toleranzia brings forward publication of annual report](#)